Understanding a key signaling pathway in acute myeloid leukemia
Official title: Elucidating the SCP4 pathway as a multi-catalytic signaling dependency in acute myeloid leukemia
Funded at Cold Spring Harbor Laboratory · NIH-10897025 · Data updated 2026-11-12
This study is looking at a specific pathway in leukemia cells to understand how it helps them survive, with the hope of finding new treatments that can better target leukemia without harming healthy cells, which could lead to better options for patients with acute myeloid leukemia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cold Spring Harbor Laboratory NIH-funded |
| Lab location | 1 site (Cold Spring Harbor, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $669,389 |
| NIH project number | 5R01CA281106-02 |
| Project ID | NIH-10897025 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia.
✕Less likely to help
Patients with other types of leukemia or those without a diagnosis of acute myeloid leukemia may not benefit from this research.
What this research studies
This research investigates the SCP4 pathway, which is crucial for the survival of acute myeloid leukemia (AML) cells. By using advanced techniques like CRISPR screening, the researchers aim to uncover how SCP4 interacts with other proteins to support AML growth. The study will explore the genetic and biochemical mechanisms behind this pathway, potentially leading to new therapeutic strategies that specifically target AML while sparing normal cells. Patients may benefit from insights gained that could lead to more effective treatments for AML.
Why it matters
Potential benefit: If successful, this research could lead to targeted therapies that improve outcomes for patients with acute myeloid leukemia.
How similar studies have gone: Previous research has shown promise in targeting similar pathways in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
-
Cold Spring Harbor Laboratory
Cold Spring Harbor, United States Active
Researchers
- Principal investigator: Vakoc, Christopher — Cold Spring Harbor Laboratory
- Study coordinator: Vakoc, Christopher
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.